Comparing the current results to its competitors, Novabridge Biosciences reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.8 %, recorded in the same quarter.
Novabridge Biosciences, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 33.44 %
Novabridge Biosciences's Comment on Competition and Industry Peers
Givastomig faces competition primarily from other CLDN18.2-targeted therapies, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. The only currently approved CLDN18.2-targeting therapy is VYLOY (zolbetuximab), marketed by Astellas. Other molecules in clinical development targeting CLDN18.2 include AstraZeneca's AZD0901/CMG901, Transcenta's osemitamab, AskGene Pharma's ASKB589, Sino Biopharmaceuticals' LM-302, and Innovent's IBI-343 and IBI-389.
VIS-101, a next-generation VEGF-A × ANG-2 bispecific antibody in Phase 2 development for wet age-related macular degeneration (AMD) and other retinal diseases, competes in a landscape dominated by two established VEGF-targeting therapies: aflibercept (Eylea® and Eylea HD®) and faricimab (Vabysmo®), the first approved VEGF-A × ANG-2 bispecific antibody. Faricimab is considered the primary competitive benchmark for VIS-101. Additional molecules are also in clinical development within this therapeutic area.
Competitors mentioned include AskGene Pharma, Astellas, AstraZeneca, Innovent, Sino Biopharmaceuticals, and Transcenta.
Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb® Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.
Sources:
Novabridge Biosciences’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Novabridge Biosciences versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
